Press release
Lupus Nephritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Roche, Equillium, BeiGene, Janssen R&D, Horizon Therapeutics, Novartis, Roche
"Lupus Nephritis Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lupus Nephritis Market.
The Lupus Nephritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Lupus Nephritis Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Lupus Nephritis treatment therapies with a considerable amount of success over the years.
*
Lupus Nephritis companies working in the treatment market are Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others, are developing therapies for the Lupus Nephritis treatment
*
Emerging Lupus Nephritis therapies in the different phases of clinical trials are- IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others are expected to have a significant impact on the Lupus Nephritis market in the coming years.
*
In March 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Gazyva Registered /Gazyvaro Registered (obinutuzumab) for the treatment of lupus nephritis. This acceptance is supported by positive findings from the Phase III REGENCY trial, which demonstrated enhanced complete renal response (CRR) when Gazyva/Gazyvaro was added to standard therapy, compared to standard treatment alone. The FDA is expected to deliver a decision on the application by October 2025.
*
In February 2025, A new phase 3, placebo-controlled study showed that adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard treatment for lupus nephritis offers greater effectiveness than standard therapy alone. At 76 weeks, 46.4% of patients receiving obinutuzumab achieved a complete renal response, compared to 33.1% in the standard therapy group. Complete renal response was defined by a urinary protein-to-creatinine ratio (UPCR) below 0.5, an estimated glomerular filtration rate (eGFR) of at least 85% of baseline, and the absence of intercurrent events such as rescue therapy, treatment failure, or early study discontinuation.
*
In February 2025, Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company focused on developing innovative small molecule therapies for immune-mediated diseases, announced its participation in a virtual Key Opinion Leader (KOL) event hosted by William Blair. The company will discuss the clinical development of zetomipzomib for autoimmune hepatitis (AIH) and share a safety update from the PALIZADE Phase 2b trial in patients with active lupus nephritis.
*
In November 2024, Adicet Bio reported that the first patient with lupus nephritis (LN) has been administered ADI-001 in a Phase I clinical trial for autoimmune diseases.
*
In November 2024, Kyverna Therapeutics announced plans to present updated clinical data on lupus nephritis (LN) patients treated with KYV-101 in the ongoing KYSA-1 and KYSA-3 Phase I/II studies, as well as named patient treatments.
*
In October 2024, Kezar Life Sciences halted subject enrollment and patient dosing in the Phase II PALIZADE trial evaluating zetomipzomib for active lupus nephritis.
*
In June 2024, Nkarta launched Ntrust-I, a multi-center clinical trial evaluating NKX019 for lupus nephritis, with the first patient undergoing screening. Additionally, the company received FDA clearance for its second Investigational New Drug (IND) application for NKX019 in autoimmune diseases.
Lupus Nephritis Overview
Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system mistakenly attacks its own tissues. In lupus nephritis, the immune system targets the kidneys, leading to inflammation and potentially causing kidney damage.
Get a Free Sample PDF Report to know more about Lupus Nephritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight [https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Lupus Nephritis Drugs Under Different Phases of Clinical Development Include:
*
Secukinumab: Novartis
*
Obinutuzumab: Roche
*
GAZYVA: Roche
*
Saphnelo (Anifrolumab): AstraZeneca
*
Iscalimab: Novartis
*
IBL-101: Inflection Biosciences
*
RG 6107: Roche
*
Itolizumab: Equillium
*
Zanubrutinib: BeiGene
*
Guselkumab: Janssen Research & Development
*
Daxdilimab: Horizon Therapeutics
*
Cosentyx: Novartis
*
Ravulizumab: Alexion Pharmaceuticals
*
Anifrolumab: AstraZeneca
Lupus Nephritis Route of Administration
Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Lupus Nephritis Molecule Type
Lupus Nephritis Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Lupus Nephritis Pipeline Therapeutics Assessment
*
Lupus Nephritis Assessment by Product Type
*
Lupus Nephritis By Stage and Product Type
*
Lupus Nephritis Assessment by Route of Administration
*
Lupus Nephritis By Stage and Route of Administration
*
Lupus Nephritis Assessment by Molecule Type
*
Lupus Nephritis by Stage and Molecule Type
DelveInsight's Lupus Nephritis Report covers around 40+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Lupus Nephritis product details are provided in the report. Download the Lupus Nephritis pipeline report to learn more about the emerging Lupus Nephritis therapies [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Lupus Nephritis Therapeutics Market include:
Key companies developing therapies for Lupus Nephritis are - N ovartis, Novartis Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Alexion Pharmaceuticals, Omeros Corporation, Corestem, Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Apellis Pharmaceuticals, AstraZeneca, Kezar Life Sciences, Equillium, Eledon Pharmaceuticals, Resolve Therapeutics, and others.
Lupus Nephritis Pipeline Analysis:
The Lupus Nephritis pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Lupus Nephritis with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis Treatment.
*
Lupus Nephritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Lupus Nephritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lupus Nephritis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Lupus Nephritis drugs and therapies [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Lupus Nephritis Pipeline Market Drivers
*
Increasing Prevalence of Lupus Nephritis, increase in research and developmental activities are some of the important factors that are fueling the Lupus Nephritis Market.
Lupus Nephritis Pipeline Market Barriers
*
However, high-cost associated with the disease, lack of awareness among the patients about the disease and other factors are creating obstacles in the Lupus Nephritis Market growth.
Scope of Lupus Nephritis Pipeline Drug Insight
*
Coverage: Global
*
Key Lupus Nephritis Companies: Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others
*
Key Lupus Nephritis Therapies: IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others
*
Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
*
Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers
Request for Sample PDF Report for Lupus Nephritis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Lupus Nephritis Report Introduction
2. Lupus Nephritis Executive Summary
3. Lupus Nephritis Overview
4. Lupus Nephritis- Analytical Perspective In-depth Commercial Assessment
5. Lupus Nephritis Pipeline Therapeutics
6. Lupus Nephritis Late Stage Products (Phase II/III)
7. Lupus Nephritis Mid Stage Products (Phase II)
8. Lupus Nephritis Early Stage Products (Phase I)
9. Lupus Nephritis Preclinical Stage Products
10. Lupus Nephritis Therapeutics Assessment
11. Lupus Nephritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Lupus Nephritis Key Companies
14. Lupus Nephritis Key Products
15. Lupus Nephritis Unmet Needs
16 . Lupus Nephritis Market Drivers and Barriers
17. Lupus Nephritis Future Perspectives and Conclusion
18. Lupus Nephritis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lupus-nephritis-pipeline-2025-fda-updates-therapy-innovations-and-clinical-trial-landscape-analysis-by-delveinsight-roche-equillium-beigene-janssen-rd-horizon-therapeutics-novartis-roche]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lupus Nephritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Roche, Equillium, BeiGene, Janssen R&D, Horizon Therapeutics, Novartis, Roche here
News-ID: 4110294 • Views: …
More Releases from ABNewswire
Congenital Hyperinsulinism Market Expected to Experience Major Growth by 2034, A …
The Key Congenital Hyperinsulinism Companies in the market include - Zealand Pharma, Rezolute, Eiger BioPharmaceuticals, Crinetics, AmideBio, Hanmi pharmaceutical, and others.
DelveInsight's "Congenital Hyperinsulinism Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Congenital Hyperinsulinism, historical and forecasted epidemiology as well as the Congenital Hyperinsulinism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Congenital Hyperinsulinism market report covers emerging…
Harpers Chimney Sweeps Expands National Reach with New Portsmouth Franchise
Harpers Chimney Sweeps, one of the UK's most trusted names in chimney care, is proud to announce the opening of a brand-new franchise in Portsmouth - marking another milestone in the company's rapid national expansion.
With established operations in Plymouth, Preston, Norfolk, and The Fylde Coast, the addition of Portsmouth represents a significant step forward in Harpers' mission to provide top-tier chimney sweeping and stove servicing across the country.
Founded on traditional…
RS Digital Launches Affordable Digital Marketing Packages for Lancashire Startup …
RS Digital, a long-established Lancashire digital marketing agency, has launched a series of affordable digital marketing packages specifically designed to help startups and small businesses grow online without blowing their budgets.
The new packages combine essential services such as SEO, Google Ads, and social media management, with flexible pricing models - ideal for businesses looking to build visibility and attract customers in their early stages.
"These packages are made for normal businesses.…
ContentKeon Leads the Pack in SEO-Driven Content Writing Services in Delhi
ContentKeon is revolutionising SEO content writing in India with its performance-first strategy rooted in quality, accuracy, and keyword knowledge. As one of the best content writing agencies in Delhi, it continues to fortify brands with actionable content that fuels growth, trust, and online visibility.
As search visibility is the key to business survival in the current digital era, Delhi's ContentKeon is a Delhi market leader in offering high-impact content writing services…
More Releases for Lupus
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Primary Catalyst Driving Lupus Therapeutics Market Evolution in 2025: Rising Res …
"What Is the Future Outlook for the Lupus Therapeutics Market's Size and Growth Rate?
The market size for lupus therapeutics has seen substantial growth in the past few years. It is projected to expand from $2.74 billion in 2024 to $2.99 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.9%. The historic growth of this market can be associated with a rise in cases of lupus, increased funding…
Key Trend Reshaping the Cutaneous Lupus Erythematosus Market in 2025: Advancemen …
What Are the Projections for the Size and Growth Rate of the Cutaneous Lupus Erythematosus Market?
The market size for cutaneous lupus erythematosus has seen quick expansion in the past few years. The growth is estimated to move from $2.24 billion in 2024 to $2.51 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.0%. This considerable increase in the historic period is a result of factors such as…
Cutaneous Lupus Erythematosus Market Trends & Analysis Report 2024
"The Business Research Company recently released a comprehensive report on the Global Cutaneous Lupus Erythematosus Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive…
Cutaneous Lupus Erythematosus (CLE) Market
Market Overview:
The Global Cutaneous Lupus Erythematosus (CLE) Market is forecasted to achieve a High CAGR during the period 2023-2030. CLE encompasses a spectrum of dermatological symptoms that may precede or accompany systemic lupus erythematosus (SLE), an autoimmune condition impacting multiple organs. Timely diagnosis and treatment of CLE can prevent the onset of severe systemic symptoms.
Market Dynamics:
Drivers:
Rise in Clinical Studies: Technological advancements leading to faster and accurate diagnosis have spurred additional…
Lupus Nephritis Treatment Market 2030
Global Lupus Nephritis Treatment market is expected to be worth roughly USD 8,048 million by 2030, growing at a CAGR of 7.3% during the forthcoming period of 2022-2030, according to Ameco Research
Lupus nephritis is one of the most rapidly spreading diseases over the globe. The increasing frequency of lupus nephritis and consumer awareness has fuelled the worldwide lupus nephritis treatment market. Another crucial factor driving the pace of growth of…
